LTZ Therapeutics

LTZs approach focuses on the fusion of reverse translational science, with a deep understanding of tumor microenvironment (TME) biology especially myeloid biology. Macrophages appear to be one of the most prevalent immune cell populations in TME of various hematologic and solid tumors. Therefore, effectively engaging and activating macrophages to k... ill cancer cells offers significant therapeutic potential for patients. LTZ is developing its own U-MCE Platform to primarily enhance the phagocytic function of monocytes and macrophages of different polarization states to foster anti-tumor immunity and offer potential therapeutic benefit for other non-oncology diseases.Read More